---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-106228"
form_type: "8-K"
ticker: "APGE"
cik: "0001974640"
company_name: "Apogee Therapeutics, Inc."
filed_at: "2025-08-11T23:59:59+00:00"
generated_at: "2026-05-17T15:48:15.430907+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Apogee reports positive APG777 Phase 2 data and Q2 net loss of $66.1M

## Summary
- APG777 APEX Part A met primary endpoint: 71.0% EASI reduction vs 33.8% placebo (p<0.001).
- Cash, cash equivalents and marketable securities at $621.2M as of June 30, 2025; runway into Q1 2028.
- Net loss of $66.1M for Q2 2025, up from $33.8M in Q2 2024, driven by higher R&D expenses.
- Phase 2 Part B readout accelerated to mid-2026; Phase 3 plans on track for 2026.
- First patient dosed in Phase 1b combination trial of APG279 vs DUPIXENT in atopic dermatitis.

## SEC filing metadata
- accession: 0000950170-25-106228
- form_type: 8-K
- ticker: APGE
- cik: 0001974640
- company_name: Apogee Therapeutics, Inc.
- filed_at: 2025-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1974640/000095017025106228/0000950170-25-106228-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1974640/000095017025106228/apge-20250811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-106228
- JSON: https://secwatch.observer/filing/0000950170-25-106228.json
- Plain text: https://secwatch.observer/filing/0000950170-25-106228.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.